Tags

Type your tag names separated by a space and hit enter

Toxic myopathies.
Continuum (Minneap Minn). 2013 Dec; 19(6 Muscle Disease):1634-49.C

Abstract

PURPOSE

This article reviews the most important muscle toxins, many of which are widely prescribed medications. Particular emphasis is placed on statins, which cause muscle symptoms in a relatively large proportion of the patients who take them.

RECENT FINDINGS

As with other toxic myopathies, most cases of statin-associated myotoxicity are self-limited and subside with discontinuation of the offending agent. Importantly, about 2% of the population is homozygous for a single nucleotide polymorphism, and these individuals have a dramatically increased risk of self-limited statin myopathy. Much more rarely, statins trigger a progressive autoimmune myopathy characterized by a necrotizing muscle biopsy and autoantibodies recognizing hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase, the pharmacologic target of statins.

SUMMARY

In most cases, toxic myopathies resolve after the toxic agent is stopped. Recognizing that statins can cause an autoimmune necrotizing myopathy is important because patients with this form of statin-triggered muscle disease usually require immunosuppressive therapy.

Authors

No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

24305451

Citation

Mammen, Andrew L.. "Toxic Myopathies." Continuum (Minneapolis, Minn.), vol. 19, no. 6 Muscle Disease, 2013, pp. 1634-49.
Mammen AL. Toxic myopathies. Continuum (Minneap Minn). 2013;19(6 Muscle Disease):1634-49.
Mammen, A. L. (2013). Toxic myopathies. Continuum (Minneapolis, Minn.), 19(6 Muscle Disease), 1634-49. https://doi.org/10.1212/01.CON.0000440663.26427.f4
Mammen AL. Toxic Myopathies. Continuum (Minneap Minn). 2013;19(6 Muscle Disease):1634-49. PubMed PMID: 24305451.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Toxic myopathies. A1 - Mammen,Andrew L, PY - 2013/12/6/entrez PY - 2013/12/7/pubmed PY - 2014/8/12/medline SP - 1634 EP - 49 JF - Continuum (Minneapolis, Minn.) JO - Continuum (Minneap Minn) VL - 19 IS - 6 Muscle Disease N2 - PURPOSE: This article reviews the most important muscle toxins, many of which are widely prescribed medications. Particular emphasis is placed on statins, which cause muscle symptoms in a relatively large proportion of the patients who take them. RECENT FINDINGS: As with other toxic myopathies, most cases of statin-associated myotoxicity are self-limited and subside with discontinuation of the offending agent. Importantly, about 2% of the population is homozygous for a single nucleotide polymorphism, and these individuals have a dramatically increased risk of self-limited statin myopathy. Much more rarely, statins trigger a progressive autoimmune myopathy characterized by a necrotizing muscle biopsy and autoantibodies recognizing hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase, the pharmacologic target of statins. SUMMARY: In most cases, toxic myopathies resolve after the toxic agent is stopped. Recognizing that statins can cause an autoimmune necrotizing myopathy is important because patients with this form of statin-triggered muscle disease usually require immunosuppressive therapy. SN - 1538-6899 UR - https://www.unboundmedicine.com/medline/citation/24305451/Toxic_myopathies_ L2 - https://doi.org/10.1212/01.CON.0000440663.26427.f4 DB - PRIME DP - Unbound Medicine ER -